Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) rose 2.8% during trading on Wednesday . The stock traded as high as $3.00 and last traded at $2.92. Approximately 19,426 shares traded hands during mid-day trading, an increase of 299% from the average daily volume of 4,872 shares. The stock had previously closed at $2.84.
Cyclerion Therapeutics Stock Up 2.7 %
The firm’s 50 day simple moving average is $2.78 and its 200 day simple moving average is $2.84.
Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.53) EPS for the quarter.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Featured Stories
- Five stocks we like better than Cyclerion Therapeutics
- Basic Materials Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Stocks to Consider Buying in October
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
